Almirall Secures China Approval for Acne Drug Seysara, Expanding Dermatology Footprint

Event summary

  • China’s NMPA approved Seysara® (sarecycline hydrochloride) for moderate-to-severe acne in patients aged 9+.
  • Seysara is the first oral antibiotic specifically developed for acne, with a favorable safety profile and low resistance potential.
  • Almirall licensed Seysara to Sinomune for exclusive commercialization in China, with expected 2026 market launch.
  • Clinical trials in China and the U.S. demonstrated efficacy, with reductions in inflammatory lesions observed as early as week 3.

The big picture

Almirall’s approval of Seysara in China marks a strategic expansion into one of the world’s largest pharmaceutical markets, where dermatology treatments are in high demand. The deal with Sinomune underscores Almirall’s focus on addressing unmet medical needs in dermatology, particularly in adolescent populations. With a growing emphasis on dermatology innovation, this approval could position Almirall as a key player in the global dermatology space.

What we're watching

Market Penetration
How Sinomune’s commercialization strategy will impact Seysara’s adoption in China’s competitive dermatology market.
Regulatory Dynamics
Whether the NMPA approval sets a precedent for faster approvals of dermatology-focused drugs in China.
Competitive Positioning
The pace at which Almirall can leverage this approval to strengthen its global dermatology portfolio.